title: Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning?
authors.affiliation: Barts Cancer Institute, Centre for Experimental Cancer Centre, Queen Mary University of London, London, UK; Royal Free Hospital NHS Foundation Trust, London, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
authors.affiliation: Barts Cancer Institute, Centre for Experimental Cancer Centre, Queen Mary University of London, London, UK.
authors.forename: Rachel
authors.initials: R
authors.lastname: Davies
authors.affiliation: Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Rini
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D020123:Sirolimus